I believe Median dosing to exceed 24 months. Given that the company reported more than 1200 patients were fully enrolled in March 2017. Simple math shows that the median patient should have been enrolled shortly thereabouts. BETonMACE officially ended in June 2019 suggesting that the median time on drug is over 25 months.

https://www.resverlogix.com/investors/news?article=565

"We have now enrolled more than 1,200 patients in BETonMACE and apabetalone remains well-tolerated with a consistent safety profile"